Propanc Biopharma reported a net loss of $4.84 million for the first quarter of its 2025/26 fiscal year, a sharp increase from the $354,000 loss recorded in the same quarter a year earlier. The company generated no revenue during the period, a typical outcome for a pre‑revenue biopharma, and ended the quarter with only $600,000 in cash, despite a $17 million balance in current assets that includes the proceeds from recent financing.
Continue reading for full analysis...
Propanc Biopharma, a development‑stage biopharmaceutical company, completed a convertible preferred stock financing with Hexstone Capital LLC that can raise up to $100 million. The transaction closed on November 10, 2025, and includes an initial $1 million investment.
Continue reading for full analysis...